Individual with concurrent chest wall tuberculosis and triplenegative essential thrombocythemia:A case report  

作　　者：Xiao-Yan Xu Yong-Bin Yang Jun Yuan Xiao-Xia Zhang Lin Kang Xiang-Shu Ma Jie Yang 

机构地区：[1]Department of Haematology,Hebei General Hospital,Shijiazhuang 050051,Hebei Province,China [2]Graduate School,Hebei North University,Zhangjiakou 075000,Hebei Province,China [3]Department of Vascular Surgery,Hebei General Hospital,Shijiazhuang 050051,Hebei Province,China [4]Department of Pathology,Hebei General Hospital,Shijiazhuang 050051,Hebei Province,China [5]Clinical Laboratory,Hebei General Hospital,Shijiazhuang 050051,Hebei Province,China

出　　处：《World Journal of Clinical Cases》2023年第22期5365-5372,共8页世界临床病例杂志

摘　　要：BACKGROUND Chest wall tuberculosis(TB)and triple-negative essential thrombocythemia(TNET)are rare medical conditions,and their combination is extremely rare globally.Only one case of TB peritonitis with thrombocytosis has been reported,which was identified in 1974.CASE SUMMARY Herein,we report the case of a 23-year-old man with concurrent chest wall mass and TN-ET.The patient presented to a local hospital due to having a headache and low-grade fever for 2 d,with their bodily temperature fluctuating at around 36.8°C.Hematological analysis showed a high platelet count of 1503×109/L.Subsequently,the patient visited our hospital for further investigation.Computed tomography of the chest suggested a submural soft tissue density shadow in the left lower chest wall.After surgical resection,the pathological findings of the swelling were reported as TB with massive caseous necrosis.According to the World Health Organization diagnostic criteria,the patient was diagnosed with TN-ET,as they met the requirement of four main criteria or the first three main criteria and one secondary criterion.The patient was eventually diagnosed with chest wall TB with TN-ET,which is extremely rare.CONCLUSION Chest wall TB is rare.TN-ET diagnosis requires secondary factor exclusion and satisfaction of primary diagnostic criteria.miRNA,combined with the methylation process,could explain suppressor of cytokine signaling(SOCS)1 and SOCS3 downregulation in ET-JAK2V617F-negative patients.The miRNA could participate in JAK2 pathway activation.SOCS3 may be a novel MPN biomarker.

关 键 词：PLATELET THROMBOCYTHEMIA TRIPLE-NEGATIVE Chest wall tuberculosis SOCS3 gene JAK-STAT pathway Case report 

分 类 号：R521.7[医药卫生—内科学]